We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
Read MoreHide Full Article
Key Takeaways
Novartis' Cosentyx receives a positive CHMP opinion for treating adolescents aged 12 and older with HS.
Supporting evidence includes adult HS studies, pharmacokinetic modeling and pediatric clinical data.
Potential EC approval would make Cosentyx Europe's only IL-17A inhibitor for adolescent HS patients.
Novartis (NVS - Free Report) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending marketing authorization for Cosentyx (secukinumab) for expanded use in hidradenitis suppurativa (HS).
The CHMP recommended Cosentyx for the treatment of adolescents aged 12 years and above with active moderate to severe HS who have had an inadequate response to conventional systemic HS therapy.
HS is a chronic and painful inflammatory skin disease characterized by recurring boil-like abscesses that can burst and cause open wounds and irreversible scarring. The disease affects as many as one in 100 people worldwide, with more than half of cases developing during adolescence.
Cosentyx is a fully human biologic that selectively targets and inhibits interleukin-17A. The drug is currently approved for several inflammatory conditions in adults, including psoriatic arthritis, moderate-to-severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis, HS and polymyalgia rheumatica.
Cosentyx also has pediatric indications, including PsO, juvenile psoriatic arthritis and enthesitis-related arthritis. In the United States, it is additionally approved for pediatric patients aged 12 years and older with moderate-to-severe HS and juvenile AS.
NVS’ Price Performance
Year to date, Novartis shares have gained 18.7% compared with the industry’s growth of 29.1%.
Image Source: Zacks Investment Research
More on the Latest CHMP Nod for NVS’ Cosentyx
The positive CHMP opinion for Cosentyx is supported by evidence showing that weight-based dosing of Cosentyx in adolescents aged 12 years and older provides drug exposure generally comparable to that observed in adults with HS.
The supporting evidence includes efficacy and safety data from adult HS clinical studies, pharmacokinetic modeling extrapolated from adult HS and psoriasis studies, pediatric clinical study data from other approved Cosentyx indications, and weight-based dosing analyses.
The safety profile of Cosentyx is well-established across several approved adult and pediatric indications.
If approved by the European Commission (EC), Cosentyx will become the only IL-17A inhibitor to be approved for adolescents with moderate-to-severe HS in Europe. It would also represent the first innovative biologic treatment option for this patient population in nearly a decade.
A final decision from the EC is expected within two months.
Cosentyx recorded sales worth $5.25 billion in the first nine months of 2026, reflecting an increase of 6% year over year at constant exchange rates. Continuous label expansion for additional indications is likely to boost sales further.
Over the past 60 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 58.2% year to date.
Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.
Over the past 60 days, estimates for Keros’ 2026 loss per share have narrowed from $5.52 to $3.73, while loss estimates for 2027 have narrowed from $6.39 to $5.31 during the same time. KROS shares have declined 49.4% year to date.
Keros’ earnings beat estimates in one of the trailing four quarters, while missing the same on the remaining three occasions, with the average surprise being 12.47%.
Over the past 60 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.13 to $7.39, while estimates for 2027 have increased from $5.34 to $6.84 during the same time. COLL shares have plunged 45.3% year to date.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.
Image: Bigstock
Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
Key Takeaways
Novartis (NVS - Free Report) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending marketing authorization for Cosentyx (secukinumab) for expanded use in hidradenitis suppurativa (HS).
The CHMP recommended Cosentyx for the treatment of adolescents aged 12 years and above with active moderate to severe HS who have had an inadequate response to conventional systemic HS therapy.
HS is a chronic and painful inflammatory skin disease characterized by recurring boil-like abscesses that can burst and cause open wounds and irreversible scarring. The disease affects as many as one in 100 people worldwide, with more than half of cases developing during adolescence.
Cosentyx is a fully human biologic that selectively targets and inhibits interleukin-17A. The drug is currently approved for several inflammatory conditions in adults, including psoriatic arthritis, moderate-to-severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis, HS and polymyalgia rheumatica.
Cosentyx also has pediatric indications, including PsO, juvenile psoriatic arthritis and enthesitis-related arthritis. In the United States, it is additionally approved for pediatric patients aged 12 years and older with moderate-to-severe HS and juvenile AS.
NVS’ Price Performance
Year to date, Novartis shares have gained 18.7% compared with the industry’s growth of 29.1%.
Image Source: Zacks Investment Research
More on the Latest CHMP Nod for NVS’ Cosentyx
The positive CHMP opinion for Cosentyx is supported by evidence showing that weight-based dosing of Cosentyx in adolescents aged 12 years and older provides drug exposure generally comparable to that observed in adults with HS.
The supporting evidence includes efficacy and safety data from adult HS clinical studies, pharmacokinetic modeling extrapolated from adult HS and psoriasis studies, pediatric clinical study data from other approved Cosentyx indications, and weight-based dosing analyses.
The safety profile of Cosentyx is well-established across several approved adult and pediatric indications.
If approved by the European Commission (EC), Cosentyx will become the only IL-17A inhibitor to be approved for adolescents with moderate-to-severe HS in Europe. It would also represent the first innovative biologic treatment option for this patient population in nearly a decade.
A final decision from the EC is expected within two months.
Cosentyx recorded sales worth $5.25 billion in the first nine months of 2026, reflecting an increase of 6% year over year at constant exchange rates. Continuous label expansion for additional indications is likely to boost sales further.
NVS Zacks Rank & Other Stocks to Consider
Novartis currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the drug/biotech sector are Vericel (VCEL - Free Report) , Keros Therapeutics (KROS - Free Report) and Collegium Pharmaceutical (COLL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 58.2% year to date.
Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.
Over the past 60 days, estimates for Keros’ 2026 loss per share have narrowed from $5.52 to $3.73, while loss estimates for 2027 have narrowed from $6.39 to $5.31 during the same time. KROS shares have declined 49.4% year to date.
Keros’ earnings beat estimates in one of the trailing four quarters, while missing the same on the remaining three occasions, with the average surprise being 12.47%.
Over the past 60 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.13 to $7.39, while estimates for 2027 have increased from $5.34 to $6.84 during the same time. COLL shares have plunged 45.3% year to date.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.